CVS Health (CVS) reported $91.23 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 2.6%. EPS of $1.83 for the same period compares to $2.21 a year ago.The reported revenue represents a surprise of -0.35% over the Zacks Consensus Estimate of $91.56 billion. With the consensus EPS estimate being $1.74, the EPS surprise was +5.17%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine the ...

KEY TAKEAWAYSCVS Health shares lost ground in early trading Wednesday after the pharmacy giant slashed its 2024 earnings guidance again amid increased medical costs.The company reported revenue for the second quarter that missed analysts' estimates, though earnings per share beat projections.CVS also announced the departure of the head of its Aetna unit. CVS Health (CVS) shares lost ground in early trading Wednesday after the pharmacy giant slashed its 2024 earnings guidance again amid increased medical cos ...

CVS Health Corporation (CVS) posted adjusted earnings per share (EPS) of $1.83 in the second quarter of 2024, down 17.2% year over year. However, the metric topped the Zacks Consensus Estimate by 5.2%. The adjusted EPS figure considers certain asset amortization costs, loss on assets held for sale and other adjustments.On a reported basis, the company’s GAAP earnings were $1.41, down 4.7% year over year.RevenuesRevenues in the second quarter rose 2.6% year over year to $91.23 billion. However, the top line ...

CVS Health (CVS) came out with quarterly earnings of $1.83 per share, beating the Zacks Consensus Estimate of $1.74 per share. This compares to earnings of $2.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.17%. A quarter ago, it was expected that this drugstore chain and pharmacy benefits manager would post earnings of $1.69 per share when it actually produced earnings of $1.31, delivering a surprise of -22.49%.Over the ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

财务业绩 - 公司总收入增长2.6%和3.1%，分别为三个月和六个月[242][249] - 医疗保健成本大幅增长27.9%和31.8%，分别为三个月和六个月[243][250] - 运营费用增长4.7%和6.0%，分别为三个月和六个月[245][250] - 营业利润下降5.8%和20.4%，分别为三个月和六个月[246][251] - 利息费用增加6.7%和13.6%，分别为三个月和六个月[247][252] - 所得税费用下降13.3%和26.4%，分别为三个月和六个月[248][253] - 净利润下降6.9%和28.6%，分别为三个月和六个月[243][251] - 公司总收入同比增长21.4%，达到324.75亿美元[278] - 医疗保险业务的医疗费用率(MBR)同比上升340个基点至89.6%[279] - 医疗保险业务的经营费用同比增长12.0%，但占总收入比重下降至13.7%[281] - 医疗保险业务的经调整经营利润同比下降39.1%，主要受到医疗利用率上升和Medicare Advantage评级下降的不利影响[282] - 公司总收入同比增长23.0%，达到647.11亿美元[283] - 医疗保险业务的医疗费用率(MBR)同比上升460个基点至90.0%[284] - 医疗保险业务的经营费用同比增长12.1%，但占总收入比重下降至13.6%[285] - 医疗保险业务的经调整经营利润同比下降50.4%，主要受到医疗利用率上升和Medicare Advantage评级下降的不利影响[286] - 总收入增加10.54亿美元，同比增长3.7%[308] - 调整后的营业利润下降1.7亿美元，同比下降12.0%，主要受到药房报销压力和前店销量下降的影响[311] - 总收入增加18.57亿美元，同比增长3.3%[314] - 调整后的营业利润下降1.27亿美元，同比下降5.0%，主要受到药房报销压力和前店销量下降的影响[318] - 总收入增加33.7%，主要由于净投资收益增加[324] - 调整后的经营亏损减少4.1%[326] - 总收入下降16.6%，主要由于净投资收益减少[327] - 调整后的经营亏损增加5.0%[329] 业务发展 - 收购Signify Health和Oak Street Health对运营产生影响[238][252] - 去年计提的重组费用和资产减值损失在本期不再发生[246][251] - 公司预计Medicare Advantage计划的会员人数将超出预期[254] - 医疗服务利用率,特别是在Medicare Advantage计划中,在2024年第二季度保持在较高水平,可能会对公司的医疗保健福利和医疗服务业务产生压力[255] - 公司的Medicaid业务正面临医疗成本压力,主要是由于成员重新认定后预期的疾病严重程度较高[255] - 公司的个人交易所业务受到风险调整计划的影响,公司需要根据其合格计划成员的风险水平相对于可比市场其他合格计划成员的平均风险水平来估计最终的风险调整应收或应付款[255] - 公司预计Cordavis、Oak Street Health和Signify Health等新业务将实现增长[255] - 公司将与客户分享更多从制药公司获得的回扣、费用和/或折扣,同时市场动态和监管变化也限制了公司向计划赞助商提供包含零售网络"差价"或"价差"的定价能力,这些趋势预计将持续[255] - GLP-1供应中断及其对产品组合的影响可能会影响公司向客户提供节省的能力,并可能影响公司的业绩[255] - 消费者支出管理和非必需消费支出下降,以及向价值、杂货和数字零售商的转移,可能会导致前店销售下降[255] - 医疗会员人数截至2024年6月30日为2700万人,较2024年3月31日增加20万人,主要反映了Medicare和Medicaid产品线的增长,包括2024年4月1日开始的Medicaid Oklahoma合同[290] - 医疗会员人数较2023年6月30日增加超过130万人,主要反映了Medicare和商业产品线的增长,部分被Medicaid产品线的下降所抵消,主要归因于2023年5月公共卫生紧急状态结束后Medicaid重新确定资格[290] - 2025年Medicare Advantage支付率的最终通知显示,预计Medicare Advantage行业的收入将平均下降0.16%,不包括CMS对Medicare Advantage风险评分趋势的估计[291] - 健康服务分部收入同比下降8.8%,主要由于之前宣布失去一个大客户以及持续的药房客户价格改善所致,部分被药品组合改善、公司医疗服务资产的贡献增加以及专科药房业务增长所抵消[295] - 健康服务分部经营费用同比增加6.9%,主要由于Oak Street Health的经营费用,包括已收购无形资产的摊销[296] - 健康服务分部经调整经营利润同比增加1.1%,主要由于采购经济性改善,部分被持续的药房客户价格改善和之前宣布失去一个大客户所抵消[297] - 处理的药房索赔量同比下降18.3%,反映了之前宣布失去一个大客户[298] - 健康服务分部的普通药品dispensing率保持相对稳定,在三个月和六个月期间均为88.2%和88.3%[299,304] - 药房同店销售增长9.1%，主要由于处方量增加6.5%和药品组合改善[309] - 前店同店销售下降4.0%，主要由于消费需求疲软和新冠检测试剂盒销量下降[309] - 处方量增加3.6%，主要由于使用量增加[312] - 普药占比上升至90.1%，主要由于新普药上市和公司鼓励使用普药[313] - 药房同店

财务业绩 - 第二季度总收入增长2.6%至912.34亿美元[2] - 第二季度GAAP每股收益为1.41美元，调整后每股收益为1.83美元[6] - 全年GAAP每股收益指引调整为4.95美元至5.20美元，调整后每股收益指引调整为6.40美元至6.65美元[3] - 公司在2024年上半年实现净利润28.92亿美元[40] - 公司在2024年上半年经营活动产生的现金流为79.92亿美元[40] - 公司在2024年第二季度调整后营业收入为37.44亿美元[47] - 公司在2023年上半年调整后营业收入为88.51亿美元[53] - 公司总收入同比增长2.6%，达到912.34亿美元[62] - 公司2024年预计调整后每股收益为6.40美元至6.65美元之间[78] - 公司2024年预计净收入为62.47亿美元至65.64亿美元之间[78] - 公司2024年预计调整后净收入为80.80亿美元至83.90亿美元之间[78] - 公司2024年预计每股摊薄收益为4.95美元至5.20美元之间[78] - 公司定义调整后营业收入为剔除无形资产摊销、已实现资本利得或损失等因素的营业收入[80] - 公司定义调整后净收入为剔除无形资产摊销、已实现资本利得或损失等因素的净收入[81] 医疗保险业务 - 医疗保险业务收入增长21.4%，但调整后营业利润下降39.1%，主要受到医疗费用上升和Medicare Advantage评级下降的影响[15,16] - 医疗保险业务医疗损失率上升至89.6%[15] - 医疗保险业务会员人数增加至2700万人[15] - 公司医疗会员总数达到2697万人，其中商业会员1880.1万人，Medicare Advantage会员434.2万人，Medicare Supplement会员129.4万人，Medicaid会员253.3万人[69] - 公司医疗保险赔付天数为43.1天[70] 医疗服务业务 - 医疗服务业务收入下降8.8%，主要受到大客户流失的影响，但调整后营业利润增长1.1%[20,21] - 健康服务业务收入同比下降9.0%，达到421.71亿美元[62] - 健康服务业务经营利润同比增长1.1%至19.15亿美元[62] - 健康服务分部收入为824.56亿美元，同比下降9.2%，主要受到药品销售收入下降的影响[71] 零售及消费者健康业务 - 零售药房及消费者健康业务收入增长3.7%，但调整后营业利润下降12.0%[23] - 零售及消费者健康业务收入同比增长3.7%，达到298.38亿美元[62] - 零售及消费者健康业务经营利润同比下降12.0%至12.43亿美元[62] - 药房及消费者健康分部收入为585.63亿美元，同比增长3.3%，主要受到药品销售收入增长的影响[72] 其他 - 公司在2024年上半年计提1亿美元的阿片类诉讼费用[51] - 公司在2023年上半年计提3.49亿美元的长期护理业务资产减值损失[53] - 公司在2023年第二季度计提4.96亿美元的重组费用[49] - 公司在2023年第二季度计提1.57亿美元的收购相关交易和整合费用[49] - 公司在2024年第二季度计提1.02亿美元的收购相关整合费用[47] - 公司在2023年第二季度计提1,100万美元的办公室房地产优化费用[49] - 公司2024年预计将发生2.02亿美元的无形资产摊销费用[78] - 公司2024年预计将发生2.40亿美元至2.30亿美元的并购整合费用[78] - 公司2024年预计将发生1.00亿美元的阿片类诉讼费用[78] - 公司2024年预计加权平均摊薄股数为12.62亿股[79]

Analyst Estimates for Q2 2024Q1 2024Q2 2023Revenue$91.54 billion$88.44 billion$88.92 billionDiluted EPS$1.3488 cents$1.48Net Income$1.69 billion$1.12 billion$1.91 billion Key Metric: Net Income CVS lowered its projections for full-year earnings per share (EPS) in its last two earnings reports, citing higher-than-expected payouts for insurance claims as Americans undergo procedures covered by insurance at a greater rate than during the pandemic. The company said in each report that it was likely that medi ...

NEW YORK, Aug. 6, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in CVS Health Corporation ("CVS" or the "Company") (NYSE: CVS) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of CVS investors who were adversely affected by alleged securities fraud between May 3, 2023 and April 30, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/cvs-health-corporation-lawsuit-submission-fo ...

The dividend payments you can receive from these high-yield stocks are yours to keep, regardless of a market correction.The past week has been a rotten one for most portfolios. On Monday, Aug. 5, the benchmark S&P 500 index began the trading session about 3% lower. That led the benchmark index to a loss of about 9.4% from its previous peak on July 16.The S&P 500 index's recent drop is nearly enough to be considered an official correction. Fear that the recent losses could become a full-blown market crash is ...